Skip to main content

US announces second round of lottery for H-1B visas

The Economic TimesBulletin

Mon, Jul 31, 2023 | 06:06 PM IST
Dear Reader,

Introducing our newest offering - The NRI Bulletin, a weekly newsletter to keep you up to date with the latest on immigration , study abroad, international jobs and NRI investments. If you would like to keep receiving this newsletter, subscribe here.

STORY OF THE WEEK

United States to conduct second lottery round for H-1B applicants this year
What's the news
The US Citizenship and Immigration Services (USCIS) has announced a second round of random lottery selection for H-1B visas for the fiscal 2024 (year ended September 30, 2024).

Possible reason
One of the reasons for a second round of lottery could be the crack down on 'fraudulent practices.'

Is this first time?
No, the US held multiple lotteries for the first time for fiscal 2022, a second lottery was held in July 2021, followed by yet another lottery in November 2021.

By Barry O'DriscollRegional Manager - India & South Asia, Education in Ireland

In today's fast-paced environment, upskilling is crucial for standing out. But it's not enough.

In Other News
1 Biden administration urged to make priority dates current for Indian Green Card applicants
2 UK opens second ballot for Young Professional visa scheme for Indians
3 Fears of greater USCIS scrutiny behind filing of lower number of H-1B petitions and second lottery
4 US student visa approval rates fall to 65%; Indians biggest winners
5 Rice export ban trigger panic-buying of food staple by Indians in the US
6 Remittances overseas, travel spends soared in May to beat TCS hit
7 Is Australia heading towards a housing crisis for international students?
8 UK university marking strike leaves thousands of students stuck in limbo
9 Australia to temporarily stop accepting TOEFL for visas
10 Russia to launch e-visa for Indians from August 1

READ MORE FROM
IMMIGRATIONSTUDYWORKINVEST
Thanks for reading.We'll be back next week with more stories and updates. Follow us on Instagram and Facebook.

Did you like today's newsletter?
hate it love it
Share your thoughts on this newsletter and recieve a 10% discount on ET Prime subscription.

* If someone forwarded this to you, subscribe here.

* If you do not want to receive this mailer, please unsubscribe here. To make sure this email is not sent to your "junk/spam" folder, select the email and add the sender to your Address Book.

© 2023 Times Internet Limited

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More